Nine-Hospital Study Comparing Broth Microdilution and Etest Method Results for Vancomycin and Daptomycin against Methicillin-Resistant Staphylococcus aureus

被引:81
作者
Sader, Helio S. [1 ]
Rhomberg, Paul R. [1 ]
Jones, Ronald N. [1 ]
机构
[1] JMI Labs, Beaver Kreek Ctr 345, N Liberty, IA 52317 USA
关键词
MINIMUM INHIBITORY CONCENTRATION; INFECTIONS; BACTEREMIA; EFFICACY; OUTCOMES; CREEP;
D O I
10.1128/AAC.00093-09
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Vancomycin and daptomycin MIC results for 1,800 randomly selected oxacillin (methicillin [meticillin])resistant Staphylococcus aureus (MRSA) bloodstream isolates from nine U. S. hospitals (collected from 2002 to 2006) were determined by a reference broth microdilution (BMD) method using frozen-form panels with precise incremental dilutions and by the Etest technique. The Etest provided vancomycin and daptomycin MIC results that were consistently higher (0.5 to 1.5 log(2) dilution steps) than those provided by the reference BMD method. The dominant MRSA population (91.2% of MRSA isolates) would be categorized as vancomycin nonsusceptible by the MIC results from the Etest method if the susceptibility breakpoint was adjusted downward to <= 1 mu g/ml, as suggested by clinical outcome studies.
引用
收藏
页码:3162 / 3165
页数:4
相关论文
共 14 条
[1]  
[Anonymous], 2006, METH DIL ANT SUSC TE, Vseventh
[2]   Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus [J].
Boucher, Helen W. ;
Sakoulas, George .
CLINICAL INFECTIOUS DISEASES, 2007, 45 (05) :601-608
[3]  
*CLIN LAB STAND I, 2008, PERF STAND ANT SUS S
[4]   High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections -: Efficacy and toxicity [J].
Hidayat, Levita K. ;
Hsu, Donald I. ;
Quist, Ryan ;
Shriner, Kimberly A. ;
Wong-Beringer, Annie .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (19) :2138-2144
[5]   Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility [J].
Howden, BP ;
Ward, PB ;
Charles, PGP ;
Korman, TM ;
Fuller, A ;
du Cros, P ;
Grabsch, EA ;
Roberts, SA ;
Robson, J ;
Read, K ;
Bak, N ;
Hurley, J ;
Johnson, PDR ;
Morris, AJ ;
Mayall, BC ;
Grayson, ML .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (04) :521-528
[6]   Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections [J].
Hsu, Donald I. ;
Hidayat, Levita K. ;
Quist, Ryan ;
Hindler, Janet ;
Karlsson, Asa ;
Yusof, Anne ;
Wong-Beringer, Annie .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 32 (05) :378-385
[8]   Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity [J].
Lodise, Thomas P. ;
Lomaestro, Ben ;
Graves, Jeffrey ;
Drusano, G. L. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (04) :1330-1336
[9]   Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections [J].
Moise-Broder, PA ;
Forrest, A ;
Birmingham, MC ;
Schentag, JJ .
CLINICAL PHARMACOKINETICS, 2004, 43 (13) :925-942
[10]   Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections [J].
Neoh H.-M. ;
Hori S. ;
Komatsu M. ;
Oguri T. ;
Takeuchi F. ;
Cui L. ;
Hiramatsu K. .
Annals of Clinical Microbiology and Antimicrobials, 6 (1)